Limits...
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.

Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P - Br. J. Cancer (2002)

Bottom Line: In univariate analysis, expression of cyclin A, Neu, Ki-67 index, and lack of OR expression were significantly associated with worse prognosis.When adjusted by the clinical model (for lymph node status, age, performance status, T-classification, grade, prior surgery, oestrogen receptor status and tamoxifen use), only overexpression of cyclin A and Neu were significantly associated with worse prognosis with hazard ratios of, respectively, 1.709 (P=0.0195) and 1.884 (P=0.0151).Overexpression of cyclin A was found in 86 out of the 201 OR-positive cases treated with tamoxifen, and was the only independent marker associated with worse prognosis (hazard ratio 2.024, P=0.0462).

View Article: PubMed Central - PubMed

Affiliation: Division of Tumour Biology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. rmichal@nki.nl

Show MeSH

Related in: MedlinePlus

(A, B) Immunohistochemical staining of breast cancer with antibody 6E6 specific for cyclin A. Note the nuclear staining with a weak cytoplasmic staining in some of the cyclin A positive tumour cells that may indicate cells at G2 phase of the cell cycle.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2375223&req=5

fig3: (A, B) Immunohistochemical staining of breast cancer with antibody 6E6 specific for cyclin A. Note the nuclear staining with a weak cytoplasmic staining in some of the cyclin A positive tumour cells that may indicate cells at G2 phase of the cell cycle.

Mentions: Cyclin A overexpression was significantly associated with overexpression of Neu, Ki-67, with expression of p53, with absence of OR, with high histological grade and high T-classification. Altogether, these associations suggest that overexpression of cyclin A is more frequently found in large size, undifferentiated, OR-negative breast tumours with an increased proliferative fraction. A representative cyclin A staining in breast cancer cells is given in Figure 3Figure 3


Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment.

Michalides R, van Tinteren H, Balkenende A, Vermorken JB, Benraadt J, Huldij J, van Diest P - Br. J. Cancer (2002)

(A, B) Immunohistochemical staining of breast cancer with antibody 6E6 specific for cyclin A. Note the nuclear staining with a weak cytoplasmic staining in some of the cyclin A positive tumour cells that may indicate cells at G2 phase of the cell cycle.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2375223&req=5

fig3: (A, B) Immunohistochemical staining of breast cancer with antibody 6E6 specific for cyclin A. Note the nuclear staining with a weak cytoplasmic staining in some of the cyclin A positive tumour cells that may indicate cells at G2 phase of the cell cycle.
Mentions: Cyclin A overexpression was significantly associated with overexpression of Neu, Ki-67, with expression of p53, with absence of OR, with high histological grade and high T-classification. Altogether, these associations suggest that overexpression of cyclin A is more frequently found in large size, undifferentiated, OR-negative breast tumours with an increased proliferative fraction. A representative cyclin A staining in breast cancer cells is given in Figure 3Figure 3

Bottom Line: In univariate analysis, expression of cyclin A, Neu, Ki-67 index, and lack of OR expression were significantly associated with worse prognosis.When adjusted by the clinical model (for lymph node status, age, performance status, T-classification, grade, prior surgery, oestrogen receptor status and tamoxifen use), only overexpression of cyclin A and Neu were significantly associated with worse prognosis with hazard ratios of, respectively, 1.709 (P=0.0195) and 1.884 (P=0.0151).Overexpression of cyclin A was found in 86 out of the 201 OR-positive cases treated with tamoxifen, and was the only independent marker associated with worse prognosis (hazard ratio 2.024, P=0.0462).

View Article: PubMed Central - PubMed

Affiliation: Division of Tumour Biology, the Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. rmichal@nki.nl

Show MeSH
Related in: MedlinePlus